Print this page
radiation
-
Targeted Genomic Analysis of Human Cancers.
Protocol: 001209Principal Investigator:
- Shridar Ganesan
Applicable Disease Sites: Any Site -
Assessing Collaborations Between Radiation Oncologists and Population
Scientists
Protocol: 002577Applicable Disease Sites: Any Site
-
Study Protocol Cancer in Pregnancy (CIP-study)
Protocol: 012201Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Any Site
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma.
Protocol: 012503Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-Like Tyrosine Kinase Mutation (FLT3 mut+): The FRIDA Study.
Protocol: 022301Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.
Protocol: 032006Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .
Protocol: 032009Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Protocol: 032409Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/ Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients.
Protocol: 032410Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Pilot Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial.
Protocol: 032411Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung